Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatment Market : Global Share, Size, Growth, Trends & Outlook ( 2022 – 2032 )

Neuromyelitis Optica Spectrum Disorder Treatment Market Insights:

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease that primarily affects the spinal cord and optic nerves in the central nervous system. Demyelination and damage to the optic nerve and spinal cord are hallmarks of this inflammatory disease. This can cause a range of symptoms, including difficulty in controlling the bladder, muscle weakness, and vision loss. Although the incidence of NMOSD is unknown, it is thought to be a rare disease, affecting less than 5 in 100,000 people.

Treatment options for NMOSD are limited and there is currently no complete cure. Most treatments are aimed at relieving symptoms and preventing future attacks. Corticosteroids such as prednisone and methylprednisolone reduce inflammation, and immunosuppressants such as rituximab, azathioprine, and mycophenolate mofetil prevent the immune system from attacking the central nervous system. During plasmapheresis, the plasma in the blood is removed and replaced to remove antibodies against the nervous system. It is often used when other treatments have failed or when a severe attack occurs. Monoclonal antibodies target specific proteins or immune cells involved in NMOSD. Satralizumab and eculizumab are the two examples.

The market for NMOSD is relatively small due to the rarity of the disease and the lack of treatment options. However, the market is expected to expand in the coming years as new treatments are developed and knowledge about the occurrence of NMOSD is gained. Treatment for NMOSD is usually individualized for each patient, and the treatment plan may change over time depending on the severity and frequency of symptoms. Collaboration with healthcare professionals experienced in the treatment of NMOSD is imperative in developing an appropriate treatment strategy.

Neuromyelitis Optica Spectrum Disorder Treatment Market Share

Accurate market share estimates for the treatment of neuromyelitis optica spectrum disorder (NMOSD) are difficult due to the rarity of the disease and the limited number of treatments available. Currently available treatments for NMOSD include corticosteroids, immunosuppressants, plasmapheresis, intravenous immunoglobulin, and rituximab. However, the specific requirements and preferences of patients and their treating physicians may determine how these treatments are used. The global market for NMOSD treatment was estimated at approx. $1.9 billion in 2021 due to the increasing prevalence of NMOSD, advances in diagnostic methods, and the development of new therapies. The market is expected to expand at a compound annual growth rate (CAGR) of around 6.2% between 2022 and 2032.

Alexion Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche Ltd., MedImmune, LLC (AstraZeneca), and UCB Pharma SA are some of the key players in the NMOSD treatment market. These companies invest in research and development to bring new treatments to market, such as monoclonal antibodies that target specific proteins involved in the immune response.

Neuromyelitis Optica Spectrum Disorder Treatment Market Key Drivers:

Several factors are driving the growth of the market for neuromyelitis optica spectrum disorder (NMOSD). Some key drivers include:

1. Advances in diagnostic methodology: The event of the latest diagnostic tools, like aquaporin 4 (AQP4) antibody tests, has improved the accuracy of NMOSD diagnosis, increasing the necessity for treatment options.
2. Aging population: As older people are more susceptible to NMOSD, the necessity for NMOSD treatment may increase.
3. New treatments in development: Monoclonal antibodies that focus on specific immune cells or proteins related to NMOSD are among the new treatments being developed by many companies and are expected to drive market expansion within the coming years.
4. Increased research funding: As more research is conducted on NMOSD, understanding of the condition may improve, resulting in new, simpler treatments. Research into NMOSD and related autoimmune diseases is receiving increased funding from governments around the world, which is predicted to steer to new and simpler treatment options.
5. Increased awareness of NMOSD: As more people study NMOSD, there could also be a greater need for treatment options.
6. Increasing prevalence of NMOSD: The worldwide demand for effective treatment options is driven by the increasing prevalence of NMOSD.
7. Reimbursement policy: Changes in medical reimbursement policies can also affect the NMOSD market. for instance, if NMOSD treatments were covered by insurance, more people could afford them, which might increase demand for them.
8. Technological development: Within the NMOSD treatment market, the appliance of advanced technologies like gene therapy is predicted to drive innovation, leading to personalized and simpler treatments.

Neuromyelitis Optica Spectrum Disorder Treatment Segmentation:

The market for neuromyelitis optica spectrum disorder (NMOSD) can be segmented based on the following factors:

1. Treatment type: Corticosteroids, Immunosuppressants, Plasma Exchange, Intravenous Immunoglobulin, Monoclonal Antibodies
2. Route of administration: Oral, Intravenous, Subcutaneous
3. End-user: Hospitals, Clinics, Homecare Settings
4. By region: North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa

Neuromyelitis Optica Spectrum Disorder Treatment Regional Synopsis

North America dominates the NMOSD treatment market due to the increasing prevalence and high awareness among patients and healthcare providers in the region. The market is expected to grow at a CAGR of around 7.5% during the forecast period (2021-2026). The market value is expected to grow from $322.6 million in 2020, to $477.8 million by 2026. The availability of state-of-the-art diagnostic tools and the increasing prevalence of NMOSD are driving the European NMOSD treatment market. In addition, the region is home to several innovative biotech companies that are contributing to the development of new treatments for NMOSD. The European therapeutics market is expected to grow at a CAGR of approximately 8.2% (2021-2026) from $229.8 million in 2020, to $378.6 million in 2026.

The Asia Pacific NMOSD treatment market is expected to grow at a CAGR of approximately 10.5% (2021-2026) from $177.9 million in 2020 to $349.8 million in 2026. Considering the large and rapidly growing population in the region, the market growth is driven by increasing disease prevalence and increasing awareness.

The Latin American NMOSD treatment market is expected to reach $113.5 million in 2026 against $79.7 million in 2020, with a CAGR of approximately 6.5% (2021-2026). This growth is fueled by the growing prevalence of the disease and the use of advanced diagnostic techniques in the region. The Middle East and African market are expected to witness moderate growth due to the same reason as Latin America. The market value is expected to reach $71.2 million in 2026 against a size of $51.6 million in 2020 with a growth of CAGR of around 5.8% (2021-2026).

Neuromyelitis Optica Spectrum Disorder Treatment share and manufacturer in Japan

Due to the increasing incidence of neuromyelitis optica spectrum disorder (NMOSD) in Japan, the market for the treatment has grown in recent years. The therapeutic market in Japan was estimated at approx. $98.9 million in 2020 and is expected to reach $325.5 million in 2027 at a CAGR of approx. 18.4% (2021-2027). Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Roche Japan are among the Japanese pharmaceutical companies that produce treatments for NMOSD. Corticosteroids, immunosuppressants, and monoclonal antibodies are among the treatments made by these businesses for NMOSD.

Neuromyelitis Optica Spectrum Disorder Treatment Market Challenges:

Several challenges may impact the market for neuromyelitis optica spectrum disorder (NMOSD). Some key challenges include:

1. Side effects of medication: Like all medicines, treatment for NMOSD can have side effects, several of which may be serious. These side effects may cause the discontinuation of treatment or the necessity for further medical intervention.
2. Competition from other markets: Other markets, such as the market for the treatment of multiple sclerosis, which is also available in the treatment of NMOSD, may compete with the market for NMOSD.
3. High medication costs: The value of medicine to treat NMOSD are often very high, especially with newer and more complex treatments. As a result, patients, healthcare systems, and insurance companies could face significant challenges.
4. Lack of awareness: As a disease that affects a little number of individuals, NMOSD remains unknown to the general public and healthcare providers. this will cause poor care and delayed diagnosis and treatment.
5. Lack of treatment options for certain patients: There are some drugs approved to treat NMOSD, but not all patients respond well to the present treatment. As a result, some patients lack treatment options. This underscores the importance of continued research and development of the latest therapies that better meet the requirements of all NMOSD patients.
6. Limited access to specialized care: Access to specialized care is restricted because NMOSD may be a complex disorder that always requires specialized care from neurologists and other physicians. However, in some places, especially rural or remote areas, access to specialist care could also be limited.

Neuromyelitis Optica Spectrum Disorder Treatment Market Key Players

Some of the key players in the market include:

1. Alexion Pharmaceuticals, Inc.: Alexion Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of NMOSD treatment such as the company's most popular drug, Soliris (eculizumab).
2. Chugai Pharmaceutical Co., Ltd.: Enspryng (satralizumab) is a monoclonal antibody for the treatment of NMOSD developed by the Japanese pharmaceutical company Chugai Pharmaceutical. The drug is approved in Europe, Japan, and the USA.
3. F. Hoffmann-La Roche Ltd.: Ocrevus (ocrelizumab), a monoclonal antibody used to treat NMOSD, was developed by Roche, a Swiss multinational healthcare company that has been approved in Europe and the United States.
4. Novartis International AG: Novartis is a Swiss multinational pharmaceutical company that has developed Ofatumumab, a monoclonal antibody used for the treatment of NMOSD, approved in the United States and Europe.
5. Sanofi S.A.: Sanofi is a French multinational pharmaceutical company that has developed Aubagio (teriflunomide), an oral medication used for the treatment of NMOSD, approved in the United States and Europe.
6. Teva Pharmaceutical Industries Ltd.: Teva Pharmaceutical Industries is an Israeli multinational pharmaceutical company that has developed Copaxone (glatiramer acetate), an injection used for the treatment of NMOSD.
7. UCB S.A.: Keppra (levetiracetam), an oral treatment for NMOSD, was developed by UCB, a multinational pharmaceutical company based in Belgium. Neurological and immunological diseases are the primary areas of research and development at UCB.